• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用交叉验证风险评分方法为两个试验终点开发预测特征。

Developing a predictive signature for two trial endpoints using the cross-validated risk scores method.

机构信息

Population Health Sciences Institute, Newcastle University, Baddiley-Clark Building, Richardson Road, Newcastle upon Tyne, NE2 4AX, UK.

Population Health Sciences Institute, Newcastle University, Baddiley-Clark Building, Newcastle upon Tyne, UK and MRC Biostatistics Unit, University of Cambridge, East Forvie Building, Forvie Site, Robinson Way, Cambridge Biomedical Campus, Cambridge, CB2 0SR, UK.

出版信息

Biostatistics. 2023 Apr 14;24(2):327-344. doi: 10.1093/biostatistics/kxaa055.

DOI:10.1093/biostatistics/kxaa055
PMID:34165151
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10102911/
Abstract

The existing cross-validated risk scores (CVRS) design has been proposed for developing and testing the efficacy of a treatment in a high-efficacy patient group (the sensitive group) using high-dimensional data (such as genetic data). The design is based on computing a risk score for each patient and dividing them into clusters using a nonparametric clustering procedure. In some settings, it is desirable to consider the tradeoff between two outcomes, such as efficacy and toxicity, or cost and effectiveness. With this motivation, we extend the CVRS design (CVRS2) to consider two outcomes. The design employs bivariate risk scores that are divided into clusters. We assess the properties of the CVRS2 using simulated data and illustrate its application on a randomized psychiatry trial. We show that CVRS2 is able to reliably identify the sensitive group (the group for which the new treatment provides benefit on both outcomes) in the simulated data. We apply the CVRS2 design to a psychology clinical trial that had offender status and substance use status as two outcomes and collected a large number of baseline covariates. The CVRS2 design yields a significant treatment effect for both outcomes, while the CVRS approach identified a significant effect for the offender status only after prefiltering the covariates.

摘要

现有的交叉验证风险评分(CVRS)设计旨在使用高维数据(如遗传数据),在高疗效患者群体(敏感群体)中开发和测试治疗效果。该设计基于为每个患者计算风险评分,并使用非参数聚类程序将它们分为聚类。在某些情况下,需要考虑两种结果(如疗效和毒性,或成本和效果)之间的权衡。基于这种动机,我们扩展了 CVRS 设计(CVRS2)以考虑两种结果。该设计采用双变量风险评分,将其分为聚类。我们使用模拟数据评估 CVRS2 的特性,并在随机精神病学试验上说明其应用。我们表明,CVRS2 能够在模拟数据中可靠地识别敏感群体(新治疗在两种结果上都有获益的群体)。我们将 CVRS2 设计应用于一项有罪犯身份和物质使用状况作为两种结果的心理学临床试验,并收集了大量的基线协变量。CVRS2 设计对两种结果都产生了显著的治疗效果,而 CVRS 方法在对协变量进行预过滤后,仅对罪犯身份识别出了显著的效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e1f/10102911/b32ac2274fbb/kxaa055f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e1f/10102911/2a49e2facbb1/kxaa055f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e1f/10102911/ebbc9cc14415/kxaa055f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e1f/10102911/b32ac2274fbb/kxaa055f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e1f/10102911/2a49e2facbb1/kxaa055f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e1f/10102911/ebbc9cc14415/kxaa055f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e1f/10102911/b32ac2274fbb/kxaa055f3.jpg

相似文献

1
Developing a predictive signature for two trial endpoints using the cross-validated risk scores method.使用交叉验证风险评分方法为两个试验终点开发预测特征。
Biostatistics. 2023 Apr 14;24(2):327-344. doi: 10.1093/biostatistics/kxaa055.
2
Developing and testing high-efficacy patient subgroups within a clinical trial using risk scores.在临床试验中使用风险评分来开发和测试高效能患者亚组。
Stat Med. 2020 Oct 30;39(24):3285-3298. doi: 10.1002/sim.8665. Epub 2020 Jul 14.
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
Cross-validated risk scores adaptive enrichment (CADEN) design.
Contemp Clin Trials. 2024 Sep;144:107620. doi: 10.1016/j.cct.2024.107620. Epub 2024 Jul 6.
5
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
6
The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.在两个欧洲药品管理局加速审批途径中使用已验证和未验证替代终点:2011-2018 年批准产品的横断面研究。
PLoS Med. 2019 Sep 10;16(9):e1002873. doi: 10.1371/journal.pmed.1002873. eCollection 2019 Sep.
7
Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).患者报告结局(PRO)在卫生技术评估(HTA)中的信息价值。
GMS Health Technol Assess. 2011 Feb 2;7:Doc01. doi: 10.3205/hta000092.
8
Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.急性缺血性脑卒中动脉内脑溶栓的试验设计与报告标准。
Stroke. 2003 Aug;34(8):e109-37. doi: 10.1161/01.STR.0000082721.62796.09. Epub 2003 Jul 17.
9
Appropriate design and reporting of superiority, equivalence and non-inferiority clinical trials incorporating a benefit-risk assessment: the BRAINS study including expert workshop.纳入获益-风险评估的优效性、等效性和非劣效性临床试验的恰当设计和报告:包含专家研讨会的 BRAINS 研究。
Health Technol Assess. 2023 Oct;27(20):1-58. doi: 10.3310/BHQZ7691.
10
Improving precision and power in randomized trials with a two-stage study design: Stratification using clustering method.
Pharm Stat. 2023 Mar;22(2):396-407. doi: 10.1002/pst.2279. Epub 2022 Dec 11.

引用本文的文献

1
Innovative trial approaches in immune-mediated inflammatory diseases: current use and future potential.免疫介导的炎症性疾病的创新试验方法:当前应用与未来潜力
BMC Rheumatol. 2021 Jul 2;5(1):21. doi: 10.1186/s41927-021-00192-5.

本文引用的文献

1
Developing and testing high-efficacy patient subgroups within a clinical trial using risk scores.在临床试验中使用风险评分来开发和测试高效能患者亚组。
Stat Med. 2020 Oct 30;39(24):3285-3298. doi: 10.1002/sim.8665. Epub 2020 Jul 14.
2
Exploratory identification of predictive biomarkers in randomized trials with normal endpoints.在具有正态终点的随机试验中探索性识别预测生物标志物。
Stat Med. 2020 Mar 30;39(7):923-939. doi: 10.1002/sim.8452. Epub 2019 Dec 21.
3
Designing precision medicine trials to yield a greater population impact.
设计精准医学试验以产生更大的人群影响。
Biometrics. 2020 Jun;76(2):643-653. doi: 10.1111/biom.13161. Epub 2019 Nov 7.
4
Semiparametric Clustering: A Robust Alternative to Parametric Clustering.半参数聚类:参数聚类的一种稳健替代方法。
IEEE Trans Neural Netw Learn Syst. 2019 Sep;30(9):2583-2597. doi: 10.1109/TNNLS.2018.2884790. Epub 2018 Dec 28.
5
Multisystemic therapy versus management as usual in the treatment of adolescent antisocial behaviour (START): a pragmatic, randomised controlled, superiority trial.多系统治疗与常规管理治疗青少年反社会行为的比较(START):一项实用、随机对照的优效性试验。
Lancet Psychiatry. 2018 Feb;5(2):119-133. doi: 10.1016/S2215-0366(18)30001-4. Epub 2018 Jan 5.
6
Adjusting for covariates in evaluating markers for selecting treatment, with application to guiding chemotherapy for treating estrogen-receptor-positive, node-positive breast cancer.在评估用于选择治疗的标志物时对协变量进行调整,并应用于指导雌激素受体阳性、淋巴结阳性乳腺癌的化疗。
Contemp Clin Trials. 2017 Dec;63:30-39. doi: 10.1016/j.cct.2017.08.004. Epub 2017 Aug 14.
7
Model-Based Recursive Partitioning for Subgroup Analyses.用于亚组分析的基于模型的递归划分
Int J Biostat. 2016 May 1;12(1):45-63. doi: 10.1515/ijb-2015-0032.
8
A Simple Method for Estimating Interactions between a Treatment and a Large Number of Covariates.一种估计治疗与大量协变量之间相互作用的简单方法。
J Am Stat Assoc. 2014 Oct;109(508):1517-1532. doi: 10.1080/01621459.2014.951443.
9
A regression tree approach to identifying subgroups with differential treatment effects.一种用于识别具有不同治疗效果亚组的回归树方法。
Stat Med. 2015 May 20;34(11):1818-33. doi: 10.1002/sim.6454. Epub 2015 Feb 5.
10
EFFECTIVELY SELECTING A TARGET POPULATION FOR A FUTURE COMPARATIVE STUDY.为未来的比较研究有效选择目标人群。
J Am Stat Assoc. 2013 Jan 1;108(502):527-539. doi: 10.1080/01621459.2013.770705.